Skip to main content
main-content

Zeitschrift

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology 1/2021

Ausgabe 1/2021

Inhaltsverzeichnis ( 14 Artikel )

03.11.2020 | Review Article | Ausgabe 1/2021

Artemisinin-type drugs for the treatment of hematological malignancies

R. I. Mancuso, M. A. Foglio, S. T. Olalla Saad

25.11.2020 | Review Article | Ausgabe 1/2021

Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs

Rajendar K. Mittapalli, Donghua Yin, Darrin Beaupre, Rameshraja Palaparthy

24.10.2020 | Original Article | Ausgabe 1/2021 Open Access

Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin

Helena Taflin, Elisabeth Odin, Göran Carlsson, Roger Tell, Bengt Gustavsson, Yvonne Wettergren

10.11.2020 | Original Article | Ausgabe 1/2021

An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib

Chenxiang Wang, Lili Ying, Mi Jin, Fangfang Zhang, Dawei Shi, Ying Dai, Ziye Zhou

04.11.2020 | Original Article | Ausgabe 1/2021 Open Access

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

Shigehisa Kitano, Toshio Shimizu, Takafumi Koyama, Takahiro Ebata, Satoru Iwasa, Shunsuke Kondo, Akihiko Shimomura, Yutaka Fujiwara, Noboru Yamamoto, Anne Paccaly, Siyu Li, Petra Rietschel, Tasha Sims

24.10.2020 | Original Article | Ausgabe 1/2021

Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

Satoshi Sai, Masanori Toyoda, Kazutoshi Tobimatsu, Hironaga Satake, Hisateru Yasui, Shiro Kimbara, Taiji Koyama, Yoshimi Fujishima, Yoshinori Imamura, Yohei Funakoshi, Naomi Kiyota, Hirochika Toyama, Yuzo Kodama, Hironobu Minami

24.10.2020 | Original Article | Ausgabe 1/2021

Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy

Daiki Tsuji, Megumi Matsumoto, Yohei Kawasaki, Yong-I. L. Kim, Keisuke Yamamoto, Hidenori Nakamichi, Yuri Sahara, Ryo Makuta, Mari Yokoi, Takehiro Miyagi, Kunihiko Itoh

07.11.2020 | Original Article | Ausgabe 1/2021

Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin

Yulin Xu, Shichong Liao, Lijun Wang, Yuan Wang, Wen Wei, Ke Su, Yi Tu, Shan Zhu

06.11.2020 | Original Article | Ausgabe 1/2021

Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients

Marina Macchini, Umberto Peretti, Giulia Orsi, Silvia Zanon, Elena Mazza, Maria Maddalena Valente, Domenico Tamburrino, Giulio Belfiori, Gemma Rossi, Sabrina Gloria Giulia Testoni, Paolo Passoni, Claudio Doglioni, Stefano Cascinu, Michele Reni

03.11.2020 | Original Article | Ausgabe 1/2021

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer

Fei-fei Han, Lu-lu Ren, Ling-ling Xuan, Ya-li LV, He Liu, Li-li Gong, Zhuo-ling An, Li-hong Liu

27.10.2020 | Original Article | Ausgabe 1/2021 Open Access

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P. Chawla, Victor Moreno, Federico Longo, Rafael Lopez, Antonio Anton, Jose Manuel Trigo, Geoffrey Shapiro, Woondong Jeong, Victor Manuel Villalobos, Rubin Lubomirov, Carlos Fernandez-Teruel, Vicente Alfaro, Valentina Boni

03.11.2020 | Original Article | Ausgabe 1/2021

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma

Long Yang, Zheyue Yuan, Yamin Zhang, Zilin Cui, Yang Li, Jiancun Hou, Xiaolong Liu, Zirong Liu, Rui Shi, Qing Tian, Jian Wang, Lianjiang Wang

19.11.2020 | Original Article | Ausgabe 1/2021

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

Tracy Murray Stewart, Daniel Von Hoff, Michael Fitzgerald, Laurence J. Marton, Carlos H. Roberto Becerra, Thomas E. Boyd, Paul R. Conkling, Lawrence E. Garbo, Robert M. Jotte, Donald A. Richards, David A. Smith, Joe J. Stephenson Jr., Nicholas J. Vogelzang, Hillary H. Wu, Robert A. Casero Jr.

12.11.2020 | Correction | Ausgabe 1/2021 Open Access

Correction to: Successful management of hyperammonemia with hemodialysis on day 2 during 5‑fluorouracil treatment in a patient with gastric cancer: a case report with 5‑fluorouracil metabolite analyses

Yoshinao Ozaki, Hirotaka Imamaki, Aki Ikeda, Mitsuaki Oura, Shunsaku Nakagawa, Taro Funakoshi, Shigeki Kataoka, Yoshitaka Nishikawa, Takahiro Horimatsu, Atsushi Yonezawa, Takeshi Matsubara, Motoko Yanagita, Manabu Muto, Norihiko Watanabe

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise